他唑巴坦

RP-HPLC法同时测定哌拉西林和他唑巴坦制剂中两组分的含量

Simultaneous Determination of Contents of Piperacillin and Tazobactam in a Preparation With RP-HPLC

RP-HPLC法测定人体液中他唑巴坦浓度及其药动学应用

Determination of the concentration of tazobactam in human plasma and urine by RP-HPLC method and its application to clinical pharmacokinetic study

HPLC测定注射用头孢噻肟钠他唑巴坦钠的含量及有关物质

Determination of two components and related substances in Cefotaxime sodium and Tazobactam sodium for injection by HPLC

对脆弱拟杆菌，哌拉西林／他唑巴坦MIC90是哌拉西林的1／8。

Against Bacteroides fragilis , the MIC 90 of piperacillin / tazobactam was 1 / 8 than that of piperacillin .

方法哌拉西林钠/他唑巴坦钠3.375g静脉滴注，每12h一次，或亚胺培南/西司他丁0.5g静脉滴注，每12h一次，治疗中、重度肺部感染，疗程为7-14d。

Methods Pipercillin / tazobactam 3.375g iv or imipenem / cilastatin 0.5g iv treated moderate and severe pulmonary infection every 12h for 7 14 days .

产ESBLs株对亚胺培南敏感率达100%，对哌拉西林/他唑巴坦敏感率为67.74%，对头孢噻肟耐药率为80.65%，对头孢他啶耐药率为19.35%。

MIC results showed that the sensitivity of ESBLs producing strains to imipenem was 100 % . And the susceptibility rate to piperacillin / tazobactam was 67.74 % . The resistance rate to cefotaxime was 80.65 % .

结果哌拉西林/他唑巴坦与头孢他啶组的有效率分别为93.8%和81.3%，细菌清除率87.8%和75.6%，两组比较差异有显著性（P0.05）；

RESULTS The effective rate , bacteria eradication rate and bacteria sensitivity rate were 93.8 % , 87.8 % and 83.3 % , respectively in piperacillin / tazobactam group , while the counterpart indexes were 81.3 % , 75.6 % and 79.5 % , respectively in ceftazidime group .

产ESBLs菌株对亚胺培南较为敏感（94.8%），其次是哌拉西林/他唑巴坦（36.1%）；而AmpC酶菌株对亚胺培南的敏感率仅为48.4%。

The ESBLs were more sensitive to imipenem ( 94.8 % ), and the next was piperacillin / tazobactam ( 36.1 % ), while the sensitive rate of the AmpC strains to imipenem were only 48.4 % .

头孢噻肟和他唑巴坦（5∶1,7∶1）治疗作用与头孢噻肟单剂相比无明显差异，ED50比较P>0.05。

The ED 50 of cefotaxime and tazobactam ( 5 ∶ 1,7 ∶ 1 ) on intraperitoneal infections showed no significant difference with that of cefotaxime alone ( P > 0.05 ) .

单次给药中剂量组10h头孢噻肟钠和他唑巴坦钠累计尿排率为49.6±0.58%和80.0±7.0%。

The cumulative urinary excretion rates of cefotaxime sodium and tazobactam sodium were ( 49.6 ± 0.58 ) % and ( 80.0 ± 7.0 ) % after intravenous drip of a single 2.4 g dose , respectively .

头孢噻肟和他唑巴坦（1∶1,3∶1）合剂对金黄色葡萄球菌产酶耐药菌腹腔感染小鼠的治疗作用明显优于头孢噻肟单剂，ED50比较P<0.01。

The therapeutic effect of cefotaxime and tazobactam ( 1 ∶ 1,3 ∶ 1 ) on intraperitoneal infections induced by β - lactamases-producing S.aureus was better than that of cefotaxime alone ( P < 0.01 ) .

目的：建立快速测定犬血浆中头孢哌酮钠和他唑巴坦钠含量的液相色谱-质谱-质谱（LC-MS-MS）联用方法。

Objective : To develop a rapid and sensitive liquid-chromatography-tandem mass spectrometry ( LC - MS-MS ) method for determination of cefoperazone sodium and tazobactam sodium in dog plasma .

1.3配伍稳定性考察的样品溶液配制分别取上述三家药厂生产的注射用哌拉西林钠他唑巴坦钠，用0.9%氯化钠注射液配制成10mg/ml哌拉西林钠，1.25mg/ml他唑巴坦钠溶液。

1.3 Preparation for Sample solutions for compatible stability investigation Piperacillin Sodium And Tazobactam Sodium For Injection from the above three manufactures were dispensed by 0.9 % sodium chloride respectively , then 10mg / ml piperacillin sodium , 1.25mg/ml tazobactam sodium can obtained . 2 .

高效液相色谱法测定注射用他唑巴坦钠/哌拉西林钠的含量

Determination of Tazobactam Sodium / Piperacillin Sodium for Injection by RP-HPLC

哌拉西林/他唑巴坦防治烧伤感染的多中心临床试验

A multicenter clinical trial of piperacillin / tazobactam in burn infection

头孢哌酮/他唑巴坦体外抗菌活性研究

Study on in vitro Antibacterial Activity of Cefperazone / Tazobactam

头孢曲松钠-他唑巴坦钠在中国健康志愿者体内的药动学

Pharmacokinetics of ceftriaxone sodium-tazobactam sodium for injection in Chinese healthy male volunteers

哌拉西林/他唑巴坦在自发性腹膜炎的临床应用

The Clinical Treatment Experience of Spontaneous Bacterial Peritonitis Using Piperacillin / Tazobactam

头孢哌酮钠他唑巴坦钠的体内抗菌作用研究

Study on antibacterial activity of cefoperazone sodium and tazobactam sodium in vivo

头孢哌酮钠/他唑巴坦钠体外抗菌活性和影响因素

In Vitro Antibacterial Activity of Cefoperazone / Tazobactam and Its impact Factors

哌拉西林/他唑巴坦治疗34例住院患者下呼吸道感染的临床研究

Piperacillin / tazobactam Treatment of 34 Inpatients with Lower Respiratory Tract Infection

哌拉西林/他唑巴坦经验治疗神经内科严重感染的观察

Empiric Therapy of Severe Infections by Piperacillin / tazobactam in Neurologic Department

哌拉西林/他唑巴坦在危重病患者感染治疗中的应用

Piperacillin / Tazobactam in Therapy against Infection in Critically Patients

不同配比头孢噻肟钠/他唑巴坦钠的体外抗菌作用

In vitro antibacterial activities of different ratios from matching cefotaxime / tazobactam

哌拉西林/他唑巴坦单用与环丙沙星联合甲硝唑治疗复杂腹腔内感染的疗效对比观察

Efficacy of Piperacillin / Tazobactam versus Ciprofloxacin plus Metronidazole for Complicated Intraabdominal Infection

哌拉西林-他唑巴坦与头孢曲松治疗下呼吸道感染的成本-效果比较

Cost-effectiveness analysis of piperacillin-tazobactam vs ceftriaxone in treatment of lower respiratory tract infection

哌拉西林钠/他唑巴坦钠治疗肺部感染的临床研究

A clinical study with piperacillin / tazobactam in the treatment of pulmonary infection

注射用哌拉西林钠/他唑巴坦钠含量测定方法的研究

Studies on Assay of Piperacillin / Tazobactam for Injection

哌拉西林/他唑巴坦治疗术后腹腔感染140例临床疗效观察

Efficacy of Piperacillin / tazobactam on Postoperative Abdominal Infection : A Clinical Investigation

结论注射用头孢噻肟钠他唑巴坦钠是一种很有发展前途的抗感染的药物。

Conclusion Cefoperazone sodium and tazobactam sodiun for injection are promising anti-infection drugs .